SLS BIO Co., Ltd (KOSDAQ:246250)

Market Cap	26.89B
Revenue (ttm)	5.47B
Net Income (ttm)	-3.57B
Shares Out	13.66M
EPS (ttm)	-237.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	285,747
Average Volume	4,356,170
Open	1,877.00
Previous Close	1,884.00
Day's Range	1,876.00 - 1,970.00
52-Week Range	1,431.00 - 5,430.00
Beta	0.74
RSI	48.32
Earnings Date	n/a

About SLS BIO

SLS BIO Co., Ltd develops diagnostic technologies in South Korea. It offers pharmaceuticals quality control testing services, including pharmaceutical equivalence study, raw materials/finished drugs test, and other analysis testing services; and efficacy evaluation services, such as immune function-based efficacy evaluation and pharmacokinetics and toxicokinetics analysis services. In addition, it provides diagnostic kits comprising rapid allergy test, rapid bovine pregnancy diagnosis, and horse individual forensic kits, as well as nano-bio tec...

• Industry: Commercial Physical and Biological Research
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246250

Financial Performance

In 2024, SLS BIO's revenue was 8.37 billion, a decrease of -7.23% compared to the previous year's 9.02 billion. Earnings were 335.63 million, a decrease of -76.60%.